EGI
VTYX

EAM Global Investors’s Ventyx Biosciences VTYX Stock Holding History

EAM Global Investors’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-46,189
Closed -$1.51M – 197
2022
Q4 		$1.51M Sell
46,189
-26,028
-36% -$771K 0.39% 137
2022
Q3 		$2.52M Buy
+72,217
New +$1.6M 0.67% 41

Other funds holding VTYX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

EAM Global Investors's VTYX Position: Q1 2023 in Review

EAM Global Investors sold out of Ventyx Biosciences (VTYX) in Q1 2023, closing a stake of 46,189 shares — an estimated $1.51M sold.

EAM Global Investors first reported a position in VTYX in Q3 2022 and held it in 2 quarters. The position peaked at $2.52M in Q3 2022. 146 funds tracked by Wall St. Rank hold VTYX as of Q1 2023.

  • EAM Global Investors reported no remaining Ventyx Biosciences position as of Q1 2023 after selling out during the quarter.
  • EAM Global Investors sold 46,189 Ventyx Biosciences shares in Q1 2023, an estimated $1.51M.
  • EAM Global Investors first reported a position in Ventyx Biosciences in Q3 2022 and held it in 2 quarters.
  • EAM Global Investors's Ventyx Biosciences position peaked at $2.52M in Q3 2022.
  • 146 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2023.

Based on EAM Global Investors's 13F filing for Q1 2023, filed 15 May 2023.